¥ 480
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of 4593.T is 643 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
